Bugworks Research, a clinical stage multi-indication therapeutics company, announced the financing of US$18M Series B1. This round will support the clinical development of BWC0977, a novel broad spectrum anti-bacterial agent available in both IV and Oral forms, and the pre-clinical development of its best-in-class Adenosine immuno-oncology asset, according to the company’s statement. The Series B1…